Combination provides an enterprise platform for comprehensive data management, analysis and compound design in drug discovery

Optibrium™ and The Edge Software Consultancy, developers of software products and services for drug discovery and development, today announced a collaboration to provide an integrated solution linking the StarDrop™ and BioRails™ platforms. The combination provides a seamless drug discovery workflow linking the latest research data directly from the lab through to decision making regarding the next round of synthesis and testing, reducing the time and cost to identify new optimisation strategies and target high quality compounds.

BioRails enables organisations to optimise the generation of high quality biological results stored in a dedicated data mart. The seamless link with StarDrop’s comprehensive capabilities for compound design, optimisation and data analysis ensures that project teams have instant access to the latest data on their compounds and can use them effectively, leading to better decisions and shorter project timelines.

The BioRails platform is designed to address a range of workflow driven research activities. BioRails can be used to design flexible processes and workflows for capturing experimental data, defining the procedures used to reliably capture high quality information. By separating design from execution BioRails provides separation between the plan and reality. This allows scientists to use the system across the full range of scientific investigations from routine activities such as ADME to more exploratory research such as in vivo behavioural studies.

Researchers can now seamlessly retrieve their biological results from BioRails using an intuitive, drag-and-drop search interface within StarDrop that enables users to easily create, share and execute database queries. StarDrop provides a highly visual way to interpret these data and their relationships with compound structures, clearly highlighting the best chemistries and multi-parameter optimisation strategies for drug discovery.

Dr Matthew Segall, CEO of Optibrium, commented: “We are delighted to be working with The Edge to provide integrated solutions to our mutual customers. We know that gaining convenient access to the latest data and using them to make good optimisation decisions is a challenge, particularly in smaller organisations without an established informatics infrastructure, and this collaboration enables us to provide a complete solution to their needs.”

“We were impressed with the design elements of Optibrium’s solutions, which rely on access to high quality results. The complimentary aspects of our solutions were clear and our experience of working together to the benefit of our customers has been very positive. We look forward to bringing this capability to many more organisations, large and small”, said Dr Andrew Lemon, The Edge’s CEO. 

more about optibrium

more news from optibrium